Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (June 2023)
29 slides from Arovella Therapeutics's investor presentation, Jun 22, 2023
Slide 1: Arovella Investor Webinar Presentation (ASX Release)
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 22 June 2023 AROVELLA INVESTOR WEBINAR PRESENTATION • Investor webinar to be held at 11 AM AEST today • Discussing next steps for Arovella and its opportunity in developing the iNKT cell platform For personal use only MELBOURNE, AUST
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cance
Slide 3: Investor Webinar June 2023
For personal use only ASX:ALA Investor Webinar June 2023
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In prepa
Slide 5: Arovella Therapeutics Highlights
Arovella Therapeutics Highlights For personal use only Off-the-Shelf iNKT Cell Platform Lead Product Advancing to Clinic Addressing Key Unmet Need Arovella is developing off-the-shelf iNKT cell ALA-101, a potential treatment for CD19-expressing Arovella’s iNKT cell platform is well therapies to targ
Slide 6: Arovella Financial Overview
Arovella Financial Overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA For personal use only $0.10 Market capitalisation1 $42.5 million 40,000,000 Shares on issue 849.9 million $0.08 30,000,000 52-week low / high1 $0.020 / $0.105 $0.06 Pro Forma Cash (March 31, 2023)2 $7.1 mil
Slide 7: Recent Milestones
Recent Milestones New data presented at AACR confirming in vitro and in vivo Positive in vitro data for activity of ALA-101 with planned Imugene Strategic clinical lentiviral vector Collaboration APR 2023 Option for cytokine technology to For personal use only enhance persistence of iNKT cells FEB 2
Slide 8: Recent Cell Therapy Transactions
Recent Cell Therapy Transactions Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Stage Upfront ($M) ($M) value ($M) May-23 License Phase Ib $245 undisclosed For personal use only Jan-23 Acquisition Phase I $200 $120 $320 Development Oct-22 Phase II $225* undisclosed collabo
Slide 9: What are CAR-T Cells?
What are “CAR-T Cells”? T cells are a common type of immune cell that fight infections and can help fight cancer For personal use only To generate autologous CAR-T cells, T cells are taken from a patient with blood cancer and ‘reprogrammed’ to produce a Chimeric Antigen Receptor (CAR) o The CAR
Slide 10: Cell Therapy Has Revolutionized Blood Cancer Treatment
Cell Therapy Has Revolutionized Blood Cancer Treatment CAR-T cells have demonstrated ability to cure haematological cancers and have generated strong sales The Cell Therapy market is expected to reach $61.2 billion by 20301 For personal use only February 2022 May 2022 Product Approval 2022 Year
Slide 11: But…Manufacturing and Logistics Pose Major Challenges
But…Manufacturing and Logistics Pose Major Challenges T cells must originate from the patient to be treated so each manufacturing batch is patient-specific Arovella’s allogeneic CAR-iNKT For personal use only cell platform has the potential to High manufacturing and supply chain costs lead to hi
Slide 12: Advantages of iNKT Cells
Advantages of iNKT Cells Cells from a healthy donor can be used to treat patients (no GvHD) iNKT cells Modify the tumour microenvironment and For personal use only kill cells that promote tumour growth Naturally target tumour cells through subpopulation of T cells with properties of invariant TCR (C
Slide 13: The Potential of CAR-iNKT Cells is Untapped
The Potential of CAR-iNKT Cells is Untapped For personal use only 11 © Copyright Arovella Therapeutics Ltd 2023 Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information
Slide 14: CAR-iNKT Cell Therapy Production Advantages
CAR-iNKT Cell Therapy Production Advantages MANUFACTURING Collect Healthy Isolate iNKT cells Engineer iNKT cells to Expand to grow billions of Vial and freeze Donor Blood produce a CAR CAR-iNKT cells CAR-iNKT cells For personal use only TREATMENT Thaw CAR-iNKT cells Allogeneic Manufacturing Advantag
Slide 15: Arovella's Potential Cancer Targets
Arovella’s Potential Cancer Targets CD19-CAR CD19-CAR DKK1-CAR For personal use only ALA-101 ALA-101 + onCARlytics ALA-104 Triple Non- Head and Prostate Brain Negative Pancreatic Multiple Hodgkin’s Lung Cancer Neck Cancer Cancer Metastases Breast Cancer Myeloma Lymphoma Cancer Additional CARs can
Slide 16: CAR19-iNKT (ALA-101)
CAR19-iNKT (ALA-101) For personal use only An off-the-shelf cell therapy for CD19-expressing cancers © Copyright Arovella Therapeutics Ltd 2023
Slide 17: CD19-expressing Blood Cancers
CD19-expressing Blood Cancers Incidence Current Treatments ALA-101 solution For personal use only CD19 is commonly expressed on Four approved autologous CAR-T ALA-101 is an off-the-shelf iNKT B cell blood cells, including: products target CD19 cell therapy that targets CD19-expressing cancer c
Slide 18: ALA-101: Superior Activity Over CAR-T Cells
ALA-101: Superior Activity Over CAR-T Cells ALA-101 significantly increased PBS T iNKT CAR19-T ALA-101 survival in mice versus treatment Ventral For personal use only with CAR19-T cells 3 Days Tumour cells expressing CD19 and CD1d were after intravenously delivered into mice treatment Dorsal Mic
Slide 19: ALA-101: Spontaneous Secondary Remission
ALA-101: Spontaneous Secondary Remission ALA-101 activity may persist to For personal use only eradicate tumour cells Ventral following relapse Four mice treated with ALA-101 had the cancer return to the brain Dorsal In all four mice, the cancer was eliminated a second time with no additional do
Slide 20: New Data Presented at AACR 2023
New Data Presented at AACR 2023 Key Highlights: For personal use only iNKT cells could be well expanded Following expansion, ALA-101 cells retained the ability to multiply further when exposed to tumour cells that express CD19 Once stimulated, ALA-101 cells express anti-cancer cytokines ALA-
Slide 21: ALA-101 Overview
ALA-101 Overview Arovella’s proprietary manufacturing process allows for efficient expansion of iNKT cells while retaining functionality For personal use only o Essential to produce multiple doses from a single batch and address the manufacturing costs and logistical challenges of current autologo
Slide 22: ALA-101 + CF33-CD19
ALA-101 + CF33-CD19 For personal use only An off-the-shelf cell therapy and oncolytic virus combination to mark and destroy solid tumours © Copyright Arovella Therapeutics Ltd 2023
Slide 23: Combining ALA-101 and CF33-CD19 (onCARlytics)
Combining ALA-101 and CF33-CD19 (onCARlytics) ALA-101 is very potent and is rapidly CF33 is an oncolytic virus that targets activated to kill CD19 expressing cancers1 tumour cells2 For personal use only The product is being developed as an off- CF33 has been engineered to induce CD19 express
Slide 24: ALA-101 + onCARlytics Mechanism of Action
ALA-101 + onCARlytics Mechanism of Action For personal use only The research collaboration progressed to in vivo testing based on promising in vitro results 22 © Copyright Arovella Therapeutics Ltd 2023
Slide 25: Milestones FY2024
Milestones FY2024 Arovella expects to advance ALA-101 into a phase I first-in-human clinical trial during 2024 Arovella also continues to assess novel complimentary technologies to expand the use of the iNKT platform to treat solid tumours For personal use only June December June 2023 2023 2024
Slide 26: Arovella Has a Strong Leadership Team
Arovella Has a Strong Leadership Team LEADERSHIP For personal use only Dr. Michael Baker Dr. Nicole van der Weerden Dr. Mini Bharathan Dr. Robson Dossa Ana Radeljevic CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER SENIOR VP DEVELOPMENT & SENIOR DIRECTOR BUSINESS DEVELOPMENT TRANSLATIONAL MEDICINE M
Slide 27: Summary – Arovella's CAR-iNKT Cell Platform
Summary – Arovella’s CAR-iNKT Cell Platform A novel allogeneic CAR-iNKT cell platform Lead product progressing to clinical trials iNKT cells serve as an excellent platform to ALA-101, a potential treatment for CD19-expressing For personal use only develop allogeneic, or “off-the-shelf”, cell blood c
Slide 28: Share Purchase Plan (SPP) Details
Share Purchase Plan (SPP) Details Oversubscribed Placement raised $4.1 million (before costs) The SPP Offer price is the same as the Placement price at $0.045 per share The Offer price represents a 10% discount to the last closing share price prior to the announcement For personal use only of
Slide 29: Thank You
Thank You For personal use only Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187 © Copyright Arovella Therapeutics Ltd 2023
Arovella Therapeutics — Investor Presentation (June 2023) on 6ix